Ligand Pharmaceuticals (LGND) Projected to Announce Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of $2.33 per share and revenue of $77.00 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.97 by $0.40. Ligand Pharmaceuticals had a return on equity of 20.06% and a net margin of 67.88%. The company had revenue of $63.69 million during the quarter, compared to analysts’ expectations of $61.30 million. During the same period last year, the business posted $1.60 earnings per share. The firm’s revenue was up 33.8% compared to the same quarter last year. On average, analysts expect Ligand Pharmaceuticals to post $5.25 EPS for the current fiscal year and $8.35 EPS for the next fiscal year.

Ligand Pharmaceuticals Trading Up 2.7%

Ligand Pharmaceuticals stock opened at $314.78 on Thursday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 30.96 and a current ratio of 31.18. The stock has a market cap of $6.28 billion, a PE ratio of 33.67, a price-to-earnings-growth ratio of 2.45 and a beta of 1.14. The stock has a 50-day moving average of $293.12 and a two-hundred day moving average of $271.15. Ligand Pharmaceuticals has a one year low of $175.89 and a one year high of $326.63.

Analysts Set New Price Targets

LGND has been the topic of several recent analyst reports. Barclays began coverage on shares of Ligand Pharmaceuticals in a report on Friday, September 25th. They set an “overweight” rating and a $345.00 price objective on the stock. Stifel Nicolaus increased their price objective on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Weiss Ratings upgraded shares of Ligand Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 21st. Bank of America lifted their target price on shares of Ligand Pharmaceuticals from $266.00 to $388.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, Royal Bank Of Canada boosted their target price on shares of Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $337.89.

Insider Transactions at Ligand Pharmaceuticals

In related news, Director Jason Haas sold 7,138 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $292.81, for a total value of $2,090,077.78. Following the transaction, the director directly owned 3,981 shares of the company’s stock, valued at $1,165,676.61. This represents a 64.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martine Zimmermann sold 1,200 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $285.00, for a total value of $342,000.00. Following the completion of the transaction, the director owned 3,897 shares of the company’s stock, valued at $1,110,645. This trade represents a 23.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 54,979 shares of company stock valued at $16,068,898 in the last quarter. Insiders own 5.60% of the company’s stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.

The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.